News Releases

Date Title and Summary
Toggle Summary electroCore Announces Publication of Study on Non-Invasive Vagus Nerve Stimulation (nVNS) to Reduce Ileus After Major Colorectal Surgery
ROCKAWAY, N.J. , Feb. 09, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer reviewed paper, entitled: “Non-invasive vagus nerve stimulation to reduce ileus after major colorectal surgery: Early
Toggle Summary electroCore to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
ROCKAWAY, N.J. , Feb. 03, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that management will participate in a fireside chat at the BTIG Virtual MedTech, Digital Health , Life Science & Diagnostic Tools Conference ,
Toggle Summary electroCore Announces Full Enrollment of TR-VENUS study of Non-Invasive Vagal Nerve Stimulation (nVNS) for the Acute Treatment of Stroke
ROCKAWAY, N.J. , Feb. 02, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that full enrollment has been achieved for the TR-VENUS study of non-invasive vagal nerve stimulation (nVNS) for the acute treatment of stroke.
Toggle Summary electroCore, Inc. Announces Inclusion of gammaCore Sapphire™ in new NHS England and NHS Improvement MedTech Funding Mandate Policy 2021/22
ROCKAWAY, N.J. , Jan. 27, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore Sapphire (nVNS) has been included in a new long-term reimbursement policy launched by Matthew Whitty , Director of Innovation
Toggle Summary electroCore, Inc. Announces Exclusive Distribution Agreement with RSK Medical Inc. in Canada
ROCKAWAY, N.J. , Jan. 26, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into an agreement with RSK Medical Inc. (“RSK Medical”) whereby RSK Medical will serve as the exclusive distributor of the
Toggle Summary electroCore, Inc. Announces Scottish Health Technology Group Recommendation For Use of gammaCore™ in NHS Scotland Cluster Headache Patients
ROCKAWAY, N.J. , Jan. 21, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Health Improvement Scotland (“HIS”) has published a Scottish Health Technology Group (“SHTG”) adaptation for NHS Scotland on the use of
Toggle Summary electroCore, Inc. Announces the Establishment of a Unique Level II HCPCS Code for “Non-Invasive Vagus Nerve Stimulator”
ROCKAWAY, N.J. , Jan. 19, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Centers for Medicare and Medicaid Services (“CMS”) published its most recent Level II Healthcare Common Procedure Coding System (“HCPCS”)
Toggle Summary electroCore Provides Business Update and Select Financial Guidance
Full year 2020 revenue expected at the upper end of previously announced guidance range of $3.3M - $3.5M ; greater than 40% growth over full year 2019 revenue of $2.4M Net cash used for the fourth quarter 2020 of $3.7 million , compares favorably to previously announced guidance of $4M December 31,
Toggle Summary electroCore, Inc. Announces Agreement with Pro Medical Baltic to be Exclusive Distributor for gammaCore Sapphire™ in Eastern Europe
ROCKAWAY, N.J. , Dec. 21, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into an agreement with Pro Medical Baltic UAB (“PMB”), whereby PMB will serve as the exclusive distributor of gammaCore
Toggle Summary electroCore Announces Positive Top-Line Results from PREMIUM II Migraine Prevention Study
BASKING RIDGE, N.J. , Dec. 08, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today top-line results from its GM-US-10 ( PREMIUM II ) study. Despite the early termination of the study in April 2020 due to the COVID-19